SCHEMBL14014135

SCHEMBL14014135

Cc1ccc(NS(=O)(=O)c2cc(Cl)c(Cl)s2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.60
CCNB1 P14635 1/20 0.60
CCNA2 P20248 1/20 0.60
CCND1 P24385 1/20 0.60
CDK2 P24941 1/20 0.60
CDK7 P50613 1/20 0.60
CCNH P51946 1/20 0.60
CCNA1 P78396 1/20 0.60
CDK6 Q00534 1/20 0.60
KIT P10721 1/20 0.56
PTGES2 Q9H7Z7 1/20 0.51
PGR P06401 1/20 0.50
NPSR1 Q6W5P4 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 1/20 0.48
HSD17B10 Q99714 1/20 0.48
HTT P42858 1/20 0.48
ACLY P53396 1/20 0.45
IKBKB O14920 1/20 0.45
CCR4 P51679 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5227591 0.80 CDK1 (0.52) CDK1CCNB1CCNA2CCND1CDK2
SCHEMBL31060131 0.75 CDK1 (1.00) CDK1CCNB1CCNA2CCND1CDK2
SCHEMBL12228293 0.74 PTGES2 (0.49) KITPTGES2ACLYIKBKBCCR4
SCHEMBL9997479 0.74 PFKFB3 (0.52) KITPTGES2L3MBTL1HSD17B10ACLY
SCHEMBL9997316 0.74 PFKFB3 (0.66) KITPTGES2POLBHSD17B10ACLY
SCHEMBL5229294 0.73 CDK1 (0.57) CDK1CCNB1CCNA2CCND1CDK2
SCHEMBL15056123 0.73 PFKFB3 (0.49) KITPTGES2NPSR1L3MBTL1POLB
SCHEMBL1775044 0.73 NPSR1 (0.50) CDK1CCNB1CCNA2CCND1CDK2
SCHEMBL12584959 0.72 POLB (0.62) CDK1CCNB1CCNA2CCND1CDK2
SCHEMBL2847555 0.72 HDAC4 (0.49) KITPTGES2L3MBTL1HTTACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR CDK1 185/4885CCNB1 227/4885CCNA2 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.